Slide 1: Exchange filing cover letter for investor presentation
October 12,2020 Shalby/SE/2020-21/75 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://www.connect2nse.com/LISTING/ Through : http://listing.bseindia.com Sub: l
Slide 2: Earnings Presentation Q2 FY2021
Earnings Presentation Q2 FY2021 SHALBY LIMITED (BSE CODE: 540797 I SHALBY, NSE CODE: SHALBY) A leader in Joint Replacement surgeries in India with an established chain of multi-specialty tertiary care hospitals.
Slide 3: Content
CONTENT 01 Q2 FY2021 PERFORMANCE HIGHLIGHTS 02 HOSPITAL BUSINESS UPDATE 2
Slide 4: Q2 FY2021 Performance Highlights
Q2 FY2021 PERFORMANCE HIGHLIGHTS
Slide 5: Q2 FY2021 Performance Highlights
Q2 FY2021 PERFORMANCE HIGHLIGHTS Quarter on quarter, Total Income up by 174% and EBITDA returned to profitability. Record high EBITDA and PAT margins of 28.0% and 21.6% respectively In Patient Count (Nos.) Surgeries Count 7,573 1,622 Total Income Operating EBITDA 3,664 in Q1 FY21 843 in Q1 FY21 Rs.
Slide 6: Key Quarter Highlights
Q2 FY2021 PERFORMANCE HIGHLIGHTS Key Quarter Highlights Commenting on performance, Mr. Shanay Shah, President Said: All our hospitals, except SG Shalby, have continued to treat Covid-19 ▪ Treated over 3,250 Covid-19 patients in total patients and provide the required infrastructure support and medic
Slide 7: Total Income, EBITDA, PBT and PAT trends
Q2 FY2021 PERFORMANCE HIGHLIGHTS Total Income (Rs. Mn) EBITDA (Rs. Mn) and Margin 1,284 1,232 307 314 1,160 1,118 243 28.0% 23.9% 19.7% 129 408 11.1% (25) Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 PBT (Rs. Mn) and Margin PAT (Rs. Mn) and Margin 215 21.6% 199 139
Slide 8: Patient counts, ARPOB and surgery count
Q2 FY2021 PERFORMANCE HIGHLIGHTS In Patients Day Care Out Patients 10,682 9,838 6,726 83,187 80,501 8,711 5,701 74,333 7,573 4,945 5,026 56,619 3,763 3,664 32,305 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 ARPOB (Rs.) Surge
Slide 9: Revenue mix, occupancy and ALOS
Q2 FY2021 PERFORMANCE HIGHLIGHTS Revenue Mix by Care % of Revenue from Arthroplasty 42% 43% 42% 12% 13% 13% 16% 11% 6% 5% 4% 4% 7% 82% 82% 83% 77% 85% 13% 12% Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 In Patient Day Care Out Patient No of Bed Occupied Occupancy
Slide 10: Revenue by Hospital Specialty
Q2 FY2021 PERFORMANCE HIGHLIGHTS Revenue by Hospital Specialty 46% 42% 13% 11% 13% 10% 9% 9% 10% 6% 8% 5% 4% 4% 5% 4% Arthroplasty Critical Care & Orthopaedic Cardiac Science Nephrology Oncology Neurology Others General Medicine Q2 FY20 Q2 FY21 Number of Surgeries by Specialty Revenues by End Patien
Slide 11: Operating expenses and cost mix
Q2 FY2021 PERFORMANCE HIGHLIGHTS Total Operating Expenses (Rs. Mn) Total Costs Mix (Rs. Mn) D&A Expenses 977 988 1,031 9% 8% 8% 10% 17% 805 9% 9% 15% 9% Other Expenses 15% 15% 14% 16% 14% 433 17% Employee Benefit Expenses 66% Purchase and Change in 63% 60% 63% 50% Inventory Operative and Other Q2 FY
Slide 12: Profit and loss statement
Q2 FY2021 PERFORMANCE HIGHLIGHTS Particulars (in Rs. Million) Q2 FY21 Q2 FY20 Q1 FY21 Q-o-Q Growth Revenue from Operations 1,093 1,258 384 185.0% Other Income 25 26 24 2.1% Total Income 1,118 1,284 408 174.0% Expenses COGS 581 722 272 113.9% % of Revenue 53% 57% 71% Employee Benefit Expenses 141 164
Slide 13: Operational Metrics
Q2 FY2021 PERFORMANCE HIGHLIGHTS Operational Metrics Q2 FY21 Q2 FY20 Q1 FY21 Q-o-Q Growth In Patient Count 7,573 10,682 3,664 106.7% (Nos.) Day Care Patient Count 5,026 6,726 3,763 33.6% (Nos.) Out Patient Count 56,619 83,187 32,305 75.3% (Nos.) Surgeries Count 1,622 4,985 843 92.4% (Nos.) ARPOB 24,
Slide 14: Hospital Business Update
SHALBY MULTI-SPECIALTY ——HOSPITALS— HOSPITAL BUSINESS UPDATE
Slide 15: Our Regional Presence
OUR REGIONAL PRESENCE Shalby has developed strong brand recognition in its core markets and is well positioned for further expansion ➢ National Presence ➢ International Presence (in Africa) PUNJAB ▪ Mohali – 145 beds RAJASTHAN ▪ Jaipur – 237 beds GUJARAT ▪ Ahmedabad o SG – 201 beds o Krishna – 220 b
Slide 16: Hospital Investment Journey
HOSPITAL INVESTMENT JOURNEY Return on Capital Employed currently reflects real estate investments and a relatively younger maturity portfolio Shalby Branding Phase Investment Phase 2 Hospitals with 228 beds Added 8 Hospitals with 1,734 new beds Q2 FY21 Occupancy of 41% reflects younger maturity Phas
Slide 17: Santa Cruz and Nashik Development Update
HOSPITAL BUSINESS UPDATE Santa Cruz Development Update Nashik Development Update Business Model: Revenue Sharing Business Model: Revenue Sharing Bed Capacity: 175 Bed Capacity: 113 Operating and Management Term: 30 + 30 years Operating and Management Term: 30 years Operationalization Year: FY 2024 O
Slide 18: SG Group, Vijay and Krishna hospitals
HOSPITAL BUSINESS UPDATE Commencement 2007 | 13 Years Catchment: Ahmedabad and surrounding areas of Gujarat, Rajasthan and Mumbai No. of beds / Occupancy 201 | 50.3% SG • Cardiac science business increased by 28.6% compared to Type of Arrangement Leased – Fixed Rent Q2 FY20 SG Group • Average occupa
Slide 19: Surat, Vapi and Indore hospitals
HOSPITAL BUSINESS UPDATE Commencement 2017 | 3 Years Catchment: South Gujarat, North Maharashtra (including Mumbai) No. of beds / Occupancy 243 | 39.1% Surat • Treated more than 600 Covid-19 patients Type of Arrangement Freehold • Highest ever occupancy in ICU Surat Group • Great response to Covid-1
Slide 20: Mohali and Jaipur hospitals
HOSPITAL BUSINESS UPDATE Commencement 2017 | 2+ Years Catchment: Punjab, Uttrakhand Mohali No. of beds / Occupancy 145 | 24.7% • Top floor dedicated for Covid-19 patients • Major specialties like arthroplasty, urology and medicine showing Type of Arrangement Freehold recovery in Q2 FY2021 • Revenue
Slide 21: Disclaimer and Contact Details
DISCLAIMER and CONTACT DETAILS No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as